DSpace Repository

Genome-level determination of Plasmodium falciparum blood-stage targets of malarial clinical immunity in the Peruvian Amazon

Show simple item record

dc.contributor.author Torres, Katherine J.
dc.contributor.author Castrillon, Carlos E.
dc.contributor.author Moss, Eli L.
dc.contributor.author Saito, Mayuko
dc.contributor.author Tenorio, Roy
dc.contributor.author Molina, Douglas M.
dc.contributor.author Davies, Huw
dc.contributor.author Neafsey, Daniel E.
dc.contributor.author Felgner, Philip
dc.contributor.author Vinetz, Joseph M.
dc.contributor.author Gamboa, Dionicia
dc.date.accessioned 2019-02-06T14:57:40Z
dc.date.available 2019-02-06T14:57:40Z
dc.date.issued 2014
dc.identifier.uri http://doi.org/10.1093/infdis/jiu614
dc.identifier.uri http://repositorio.upch.edu.pe/handle/upch/5490
dc.description.abstract BACKGROUND: Persons with blood-stage Plasmodium falciparum parasitemia in the absence of symptoms are considered to be clinically immune. We hypothesized that asymptomatic subjects with P. falciparum parasitemia would differentially recognize a subset of P. falciparum proteins on a genomic scale. METHODS AND FINDINGS: Compared with symptomatic subjects, sera from clinically immune, asymptomatically infected individuals differentially recognized 51 P. falciparum proteins, including the established vaccine candidate PfMSP1. Novel, hitherto unstudied hypothetical proteins and other proteins not previously recognized as potential vaccine candidates were also differentially recognized. Genes encoding the proteins differentially recognized by the Peruvian clinically immune individuals exhibited a significant enrichment of nonsynonymous nucleotide variation, an observation consistent with these genes undergoing immune selection. CONCLUSIONS: A limited set of P. falciparum protein antigens was associated with the development of naturally acquired clinical immunity in the low-transmission setting of the Peruvian Amazon. These results imply that, even in a low-transmission setting, an asexual blood-stage vaccine designed to reduce clinical malaria symptoms will likely need to contain large numbers of often-polymorphic proteins, a finding at odds with many current efforts in the design of vaccines against asexual blood-stage P. falciparum.
dc.language.iso eng
dc.publisher Oxford University Press
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Adolescent
dc.subject Adult
dc.subject Female
dc.subject Humans
dc.subject Male
dc.subject Young Adult
dc.subject Child
dc.subject Middle Aged
dc.subject immunology
dc.subject malaria
dc.subject Antibodies, Protozoan/immunology
dc.subject Antigens, Protozoan/genetics/immunology
dc.subject geographic medicine
dc.subject Malaria Vaccines/immunology
dc.subject Malaria, Falciparum/blood/immunology
dc.subject Parasitemia/blood/immunology/parasitology
dc.subject Plasmodium falciparum/genetics/immunology
dc.subject Protozoan Proteins/blood/genetics/immunology
dc.subject systems biology
dc.title Genome-level determination of Plasmodium falciparum blood-stage targets of malarial clinical immunity in the Peruvian Amazon
dc.type info:eu-repo/semantics/article
dc.identifier.journal Journal of Infectious Diseases

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account